INTRODUCTION
Oxygen-derived species such as 02-and H202 have been implicated as damaging agents in the action ofmany toxins and in a number of diseases [1, 2] . The possibility that much of the toxicity produced by increased O2-and H202 generation is mediated by metal-ion-dependent formation ofthe highly reactive OH radical has also been discussed in detail [3] [4] [5] . Although much circumstantial evidence supports the biological relevance of the iron-ion-catalysed formation of'OH radical from O2-and and H202 [3, 4, 6] , there has been as yet no direct demonstration that 'OH radical is formed in vivo. The inflamed rheumatoid joint, in which conditions are proposed to be ideal for OH generation [4] , seems a good place to look.
The 'OH radical is so highly reactive that proving its formation in vivo will be correspondingly difficult. Spin traps such as 5,5-dimethylpyrroline N-oxide (DMPO) do not seem promising for the detection of OH in vivo [7] , nor does the conversion of 4-methylthio-2-oxobutyrate into ethene [19] . Hence we have attempted to adapt our technique for measuring ' OH radicals in vitro, aromatic hydroxylation [8] [9] [10] , for use in vivo. Aromatic compounds react with high rate constants with 'OH, often to form a specific set of hydroxylated products [1 1, 12] . If an aromatic compound can be safely administered to humans in doses that produce concentrations in body fluids sufficient to scavenge OH, then observation of those products expected from attack of OH on the aromatic compound would be good evidence that OH is being formed in vivo, provided that the same products are not formed by enzymic hydroxylating systems.
Aspirin (O-acetylsalicylate) is still sometimes used in the treatment of rheumatoid arthritis. It is rapidly hydrolysed to salicylate in vivo [14, 15] . Attack of 'OH upon salicylate produces two products that have not been reported as normal products of enzymic salicylate metabolism, namely 2,3-dihydroxybenzoate and, to a much smaller extent, catechol [12, 15, 16] . We (Fig. la) . Ether extracts of plasma samples from volunteers not taking aspirin showed no interfering peaks at this position (Fig. lb) . Plasma from healthy volunteers taking aspirin showed a peak at this position (Fig. Ic shows a typical example). However, in the small number of samples of plasma and synovial fluid from rheumatoid patients that have been studied to date, peaks of greater intensity were generally observed (e.g. Fig. ld) .
The retention time of the putative 2,3-dihydroxybenzoate peak in biological fluid samples relative to the 3,4-dihydroxybenzoate standard was 0.849 + 0.008 (mean + S.D., n = 6), exactly the same as the value obtained in standard runs (Figs. la). By this assay method, plasma from patient A contained 230 nM-2,3-dihydroxybenzoate, and knee-joint synovial fluid from the same patient contained 240 nM-2,3-dihydroxybenzoate. These values varied by less than 5% in different runs. The 2,3-dihydroxybenzoate was quantified on the basis of standard plots of the ratio of its peak height to that of the internal standard 3,4-dihydroxybenzoate against 2,3-dihydroxybenzoate concentration at fixed 3,4-dihydroxybenzoate concentration. Although gentisate has a retention time very close to the internal standard (see the text), it was not found to alter significantly the peak height of the internal standard. The response of the electrochemical detector was directly proportional to 2,3-dihydroxybenzoate concentration in the range 0-20/M.
In view of the large number of ether-soluble molecules present in biological fluids, an identity of relative retention times with those of a standard is inadequate evidence to attribute the peak to 2,3-dihydroxybenzoate. Two methods were used to confirm its identity. Firstly, the oxidation potential of the detector was varied in the range 0.30-0.68 V. Fig. 2 shows that the height of the putative 2,3-dihydroxybenzoate peak (expressed relative to its height at 0.68 V) varied in exactly the same way as that for a 2,3-dihydroxybenzoate standard. Other phenolic compounds give different oxidation potential curves (results not shown). Secondly, the eluent composition was varied by including methanol at concentrations up to 6% (v/v), producing large changes in retention times. However, the putative 2,3-dihydroxybenzoate peak in synovial-fluid and plasma samples gave retention times relative to the internal standard that were always identical with those given by an authentic sample of 2,3-dihydroxybenzoate.
Hence we conclude that method A provides an accurate measurement of 2,3-dihydroxybenzoate concentrations in human plasma and synovial fluid, provided that the identity of the peaks is always confirmed by the above procedures. Method B
The eluent was changed to include 2.8% (v/v) methanol and a higher oxidation potential was used for the detector, so that salicylate could be measured (for full details see the legend to Fig. 3 ). The main difference was that ethyl acetate was used to extract the biological fluids, instead ofdiethyl ether. Unlike diethyl ether, ethyl acetate is allegedly specific for the extraction of phenolic acids [20] . However, we found this not to be absolutely true. The oxidation potential of the detector was varied and the height of the putative 2,3-dihydroxybenzoate peak in rheumatoid synovial fluid was measured. The relative peak height is plotted as a function of oxidation potential (0).
Similar experiments were conducted with a 2,3-dihydroxybenzoate standard (0) and it may be seen that the two curves match closely. ly extraction procedure. None of the compounds was present in measurable amount in the 'blank' serum sample (Fig. 3b) were identical with those shown by the authentic compounds ( Fig. 2 illustrates the principle of this method). Table 1 shows some typical analytical results obtained by applying method B to human body fluids. The values obtained for 2,3-dihydroxybenzoate were, in a series of runs, within 5% of these given by method A. The results in Table 1 emphasize the point that the product of interest in this study (2,3-dihydroxybenzoate) is present in concentrations about two orders of magnitude less than the 'major' metabolites of salicylate, such as salicylurate. Method C By changing the eluent to 96% citrate/acetate buffer (pH 4.75)/4% (v/v) methanol, it was found possible to separate catechol and salicylate (retention times on a typical chromatogram were 11.8 min for catechol and 13.4 min for salicylate at an eluent flow rate of 1.0 ml/min and ambient temperature). Diethyl ether extracts of rheumatoid synovial fluid (patient A) were analysed on this system. It was necessary to extract 3.4 ml of synovial fluid in order to obtain a measurable peak in the region at which catechol would be expected to run. We were unable to obtain clear evidence that this peak was in fact catechol. However, these studies did show that the amount of catechol apparently present was insignificant in relation to the amount of salicylate (see the legend to Table 1 ).
DISCUSSION
Attack by OH radicals, generated by a Fenton system at pH 7.4, upon salicylate produces three products (Scheme 1). Formation of the decarboxylation product catechol has not been reported in previous experiments in which salicylate was exposed to Fenton systems under physiological conditions [9, 16] , but its formation is not unexpected, since radiolysis ofaerated salicylate solutions produces some catechol [17] . Also, decarboxylation of benzoate has been used as assay for 'OH radicals in vitro [18] Salicylate reacts with OH with a rate constant ofabout 5 x 109-101o M-l s-1 [21] . The fairly low oral doses of aspirin used in our studies gave body-fluid salicylate concentrations of up to 0.4 mm, which might feasibly intercept some OH radicals, to an extent depending on the concentrations, and reaction rate constants, for other molecules present that react with OH radicals. If oral aspirin is increased to about 4.2 g daily, fluid salicylate concentrations rise to over 0.8 mm [22] . The limited studies performed to date suggest that salicylate, and products derived from it, are present in the synovial fluids at concentrations similar to those in plasma. The purpose of the present paper is to describe chromatographic methods for the specific identification and quantification in bodyfluids ofproducts of OH attack on salicylate, in the hope that the methodology may be of use to scientists attempting to detect and measure OH generation in other examples of oxidative stress. 2,3-Dihydroxybenzoate can be accurately measured by the techniques described here, whereas catechol, which is formed in much smaller amounts by OH attack (Scheme 1), seems a less promising product to measure (see under 'Method C' in the Results section).
We stress that the limited studies on human samples reported in the present paper in no way prove that the 2,3-dihydroxybenzoate detected in body fluids does originate from radical attack on salicylate. Indeed, the presence of low concentrations of this product in the plasma of healthy human volunteers after aspirin ingestion might be taken to suggest that it can be generated by a previously unreported minor metabolic pathway. It might also be related to the 'baseline' rate of intracellular OH formation from ionizing radiation and Fenton reactions [2] . Further work to investigate the origin of 2,3-dihydroxybenzoate is therefore required. It should also be noted that the principle behind our methodology can be applied to other aromatic compounds.
